Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3005 Combination Therapy in Advanced Solid Tumors
NCT07612137Phase 2Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3005 in non-small cell lung cancer (NSCLC), sponsored by Innovent Biologics. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
IBI3005
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07612137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612137.